Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Maintenance Therapy With Pazopanib Delays Relapse of Advanced Ovarian Cancer
June 2nd 2013, 7:03am
An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.
Dr. Tewari on Bevacizumab in Advanced Cervical Cancer
June 2nd 2013, 6:15am
Krishnansu S. Tewari, MD, from the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.
Cetuximab OS Results Top Bevacizumab in mCRC
June 2nd 2013, 5:35am
Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.
Nivolumab Delivers Enduring Benefits in Advanced Melanoma
June 2nd 2013, 5:26am
Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.
Dr. Sznol Describes Nivolumab in Advanced Melanoma
June 2nd 2013, 5:23am
Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.
Dr. D'Souza on Spouses of HPV-Positive Patients
June 1st 2013, 11:41am
Gypsyamber D‘Souza, PhD, MPH, MS, from Johns Hopkins University, discusses the prevalence of oral HPV infections in the spouses of patients with HPV-positive oropharyngeal cancer.
Dr. du Bois on Pazopanib in Advanced Ovarian Cancer
June 1st 2013, 10:03am
Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma
June 1st 2013, 8:57am
Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.
ASCO Highlights Put Variety in Spotlight
June 1st 2013, 6:15am
New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.
Dr. O'Shaughnessy on Everolimus in Breast Cancer
June 1st 2013, 5:22am
Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.
ASCO Opens 49th Annual Meeting Urging More Federal Funding for Research
June 1st 2013, 5:15am
The American Society of Clinical Oncology kicked off its 49th Annual Meeting with leaders urging all stakeholders in cancer care to vigorously oppose cuts to vital US biomedical research funding.
Dr. Pazdur on Breakthrough Designation Requirements
May 31st 2013, 1:03pm
Richard Pazdur, MD, from the FDA's Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.
Combining Ipilimumab and Nivolumab Shows Promise in Advanced Melanoma
May 16th 2013, 4:55pm
Combining the checkpoint antibodies ipilimumab and nivolumab led to deep tumor regression in approximately one-third of patients with advanced melanoma.
High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer
May 15th 2013, 2:07pm
Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.
New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukemia
May 15th 2013, 2:02pm
The novel selective PI3K-delta inhibitor idelalisib produced rapid and prolonged tumor shrinkage in patients with relapsed or refractory chronic lymphocytic leukemia who received the drug as a monotherapy.
Adjuvant Surveillance Effective in Early-Stage Seminoma
May 15th 2013, 2:02pm
Active surveillance following radical orchiectomy is an effective treatment strategy for men with stage I seminoma.
Follow-Up Scans Do Little to Detect Relapse of Diffuse Large B-Cell Lymphoma
May 15th 2013, 2:01pm
Routine follow-up imaging is of limited value in determining whether patients with diffuse large B-cell lymphoma have experienced a relapse of their disease.
In Treating Locally Advanced NSCLC, More Radiotherapy Is Not Better
May 15th 2013, 2:00pm
Radiotherapy at a higher-than-standard dose is harmful to patients with locally advanced non-small cell lung cancer who are also getting concurrent and consolidation chemotherapy.
Early Results Robust for New PD-L1 Immunotherapy Agent
May 15th 2013, 6:07am
An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.
Dramatic Shortage of Urologists on Horizon
May 6th 2013, 4:05pm
An estimated 16,000 urologists will be needed to provide specialty care by 2025, but estimates of the number of urologists likely to be in practice at that time range between 6800 and 7400.